Loading clinical trials...
Loading clinical trials...
A Double-Blind Discontinuation Study of Levetiracetam in Post- Traumatic Stress Disorder
The purpose of this study is to evaluate the short-term efficacy and safety of levetiracetam in post-traumatic stress disorder (PTSD) and to evaluate continuation effects of levetiracetam in preventing PTSD relapse. The hypothesis is that levetiracetam will be safe and effective in preventing relapse of PTSD.
This is an investigator-initiated, single site study, consisting of two phases: 8 weeks of open label treatment with levetiracetam (500-2000 mg/day) in patients with PTSD, and in those who demonstrate at least minimal improvement, 12 weeks of randomized, double-blind treatment with either levetiracetam or matching placebo.
Age
18 - 65 years
Sex
ALL
Healthy Volunteers
No
Duke University Medical Center
Durham, North Carolina, United States
Start Date
November 1, 2005
Primary Completion Date
September 1, 2007
Completion Date
March 1, 2008
Last Updated
July 21, 2014
16
ACTUAL participants
levetiracetam
DRUG
Placebo
DRUG
Levetriracetam
DRUG
Lead Sponsor
Duke University
Collaborators
NCT07447089
NCT06516874
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions